Tyra Biosciences details Q2 2025 earnings release

Tyra Biosciences, Inc. furnished a current report to note that it has issued a press release announcing its financial results for the quarter ended June 30, 2025.

Accepted by SEC EDGAR 08/14/2025 - 04:11 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Tyra Biosciences, Inc. furnished a current report to note that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release, dated August 14, 2025, is included as Exhibit 99.1 to this report and is incorporated by reference. The company specifies that this earnings information, including the exhibit, is being furnished rather than filed, which limits how it is treated under certain liability provisions of U.S. securities laws.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tyra Biosciences (TYRA) disclose in this 8-K filing?

Tyra Biosciences disclosed that it issued a press release announcing its financial results for the quarter ended June 30, 2025, and attached that release as Exhibit 99.1.

Which period’s results are covered by Tyra Biosciences’ latest earnings press release?

The press release covers Tyra Biosciences’ financial results for the quarter ended June 30, 2025.

When did Tyra Biosciences issue the press release about its quarterly results?

Tyra Biosciences issued the press release on August 14, 2025, and identified it as Exhibit 99.1.

How is the Tyra Biosciences earnings information treated under securities laws?

The company states that the earnings information in this report, including Exhibit 99.1, is being furnished under Item 2.02 rather than filed, so it is not subject to Section 18 liability under the Exchange Act.

Which exhibit in the Tyra Biosciences 8-K contains the quarterly results press release?

Exhibit 99.1 contains the press release that announces Tyra Biosciences’ financial results for the quarter ended June 30, 2025.

Who signed the Tyra Biosciences 8-K related to the quarterly results?

The report was signed on behalf of Tyra Biosciences, Inc. by Alan Fuhrman, Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000186312700018631272025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

Tyra Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40800	83-1476348
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2656 State Street
Carlsbad, California				92008
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (619) 728-4760

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		TYRA		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release Issued on August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			TYRA BIOSCIENCES, INC.
Date:	August 14, 2025	By:	/s/ Alan Fuhrman
			Alan Fuhrman Chief Financial Officer